LegoChem Biosciences Inc (141080) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LegoChem Biosciences Inc (141080) has a cash flow conversion efficiency ratio of -0.022x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-12.15 Billion ≈ $-8.24 Million USD) by net assets (₩563.07 Billion ≈ $381.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
LegoChem Biosciences Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how LegoChem Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read LegoChem Biosciences Inc total liabilities for a breakdown of total debt and financial obligations.
LegoChem Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LegoChem Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sinotrans Ltd Class A
SHG:601598
|
0.044x |
|
Sinomach Heavy Equipment Group Co Ltd
SHG:601399
|
-0.020x |
|
Rising Nonferrous Metals Share Co Ltd
SHG:600259
|
0.103x |
|
GPGI, Inc.
NYSE:GPGI
|
-0.058x |
|
TG Therapeutics Inc
NASDAQ:TGTX
|
-0.038x |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
-0.004x |
|
KURITA WTR IND.UNSP.ADR 2
F:KWI0
|
N/A |
|
LEG Immobilien SE
XETRA:LEG
|
0.017x |
Annual Cash Flow Conversion Efficiency for LegoChem Biosciences Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of LegoChem Biosciences Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of LegoChem Biosciences Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩616.00 Billion ≈ $417.45 Million |
₩78.48 Billion ≈ $53.18 Million |
0.127x | +130.34% |
| 2023-12-31 | ₩148.22 Billion ≈ $100.45 Million |
₩-62.24 Billion ≈ $-42.18 Million |
-0.420x | -1192.20% |
| 2022-12-31 | ₩219.60 Billion ≈ $148.82 Million |
₩-7.14 Billion ≈ $-4.84 Million |
-0.032x | +80.00% |
| 2021-12-31 | ₩258.77 Billion ≈ $175.37 Million |
₩-42.05 Billion ≈ $-28.50 Million |
-0.162x | -22.33% |
| 2020-12-31 | ₩112.13 Billion ≈ $75.99 Million |
₩-14.89 Billion ≈ $-10.09 Million |
-0.133x | -162.66% |
| 2019-12-31 | ₩113.75 Billion ≈ $77.09 Million |
₩24.11 Billion ≈ $16.34 Million |
0.212x | +268.92% |
| 2018-12-31 | ₩101.66 Billion ≈ $68.90 Million |
₩-12.76 Billion ≈ $-8.65 Million |
-0.125x | +26.34% |
| 2017-12-31 | ₩48.21 Billion ≈ $32.67 Million |
₩-8.21 Billion ≈ $-5.57 Million |
-0.170x | +21.52% |
| 2016-12-31 | ₩60.06 Billion ≈ $40.70 Million |
₩-13.04 Billion ≈ $-8.84 Million |
-0.217x | -9.73% |
| 2015-12-31 | ₩43.18 Billion ≈ $29.26 Million |
₩-8.54 Billion ≈ $-5.79 Million |
-0.198x | +49.69% |
| 2014-12-31 | ₩20.04 Billion ≈ $13.58 Million |
₩-7.88 Billion ≈ $-5.34 Million |
-0.393x | -- |
About LegoChem Biosciences Inc
LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical devic… Read more